208 related articles for article (PubMed ID: 33558663)
21. B7-H3 Expression in Breast Cancer and Brain Metastasis.
Joshi V; Beecher K; Lim M; Stacey A; Feng Y; Jat PS; Duijf PHG; Simpson PT; Lakhani SR; McCart Reed AE
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612786
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial.
Shenderov E; De Marzo AM; Lotan TL; Wang H; Chan S; Lim SJ; Ji H; Allaf ME; Chapman C; Moore PA; Chen F; Sorg K; White AM; Church SE; Hudson B; Fields PA; Hu S; Denmeade SR; Pienta KJ; Pavlovich CP; Ross AE; Drake CG; Pardoll DM; Antonarakis ES
Nat Med; 2023 Apr; 29(4):888-897. PubMed ID: 37012549
[TBL] [Abstract][Full Text] [Related]
23. B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3.
Lin L; Cao L; Liu Y; Wang K; Zhang X; Qin X; Zhao D; Hao J; Chang Y; Huang X; Liu B; Zhang J; Lu J; Ge Q
Leukemia; 2019 Jun; 33(6):1475-1486. PubMed ID: 30573782
[TBL] [Abstract][Full Text] [Related]
24. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome.
Zang X; Thompson RH; Al-Ahmadie HA; Serio AM; Reuter VE; Eastham JA; Scardino PT; Sharma P; Allison JP
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19458-63. PubMed ID: 18042703
[TBL] [Abstract][Full Text] [Related]
25. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.
Borno HT; Cowan JE; Zhao S; Broering JM; Carroll PR; Ryan CJ
Urol Oncol; 2020 Oct; 38(10):793.e1-793.e11. PubMed ID: 32782182
[TBL] [Abstract][Full Text] [Related]
26. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
Mendes AA; Lu J; Kaur HB; Zheng SL; Xu J; Hicks J; Weiner AB; Schaeffer EM; Ross AE; Balk SP; Taplin ME; Lack NA; Tekoglu E; Maynard JP; De Marzo AM; Antonarakis ES; Sfanos KS; Joshu CE; Shenderov E; Lotan TL
Cancer; 2022 Jun; 128(12):2269-2280. PubMed ID: 35333400
[TBL] [Abstract][Full Text] [Related]
27. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
[TBL] [Abstract][Full Text] [Related]
28. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis.
Wang L; Zhang Q; Chen W; Shan B; Ding Y; Zhang G; Cao N; Liu L; Zhang Y
PLoS One; 2013; 8(8):e70689. PubMed ID: 23940627
[TBL] [Abstract][Full Text] [Related]
29. Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer.
Lv C; Han S; Wu B; Liang Z; Li Y; Zhang Y; Lang Q; Zhong C; Fu L; Yu Y; Xu F; Tian Y
Front Immunol; 2022; 13():984172. PubMed ID: 36159808
[TBL] [Abstract][Full Text] [Related]
30. Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis.
Barata PC; Magi-Galluzzi C; Gupta R; Dreicer R; Klein EA; Garcia JA
Clin Genitourin Cancer; 2019 Oct; 17(5):366-372. PubMed ID: 31262501
[TBL] [Abstract][Full Text] [Related]
31. Evaluation Challenges in the Validation of B7-H3 as Oral Tongue Cancer Prognosticator.
Sieviläinen M; Wirsing AM; Hyytiäinen A; Almahmoudi R; Rodrigues P; Bjerkli IH; Åström P; Toppila-Salmi S; Paavonen T; Coletta RD; Hadler-Olsen E; Salo T; Al-Samadi A
Head Neck Pathol; 2021 Jun; 15(2):469-478. PubMed ID: 32959211
[TBL] [Abstract][Full Text] [Related]
32. Assessment of combined expression of B7-H3 and B7-H4 as prognostic marker in esophageal cancer patients.
Chen L; Xie Q; Wang Z; Shi L; Wu C; Jiang J
Oncotarget; 2016 Nov; 7(47):77237-77243. PubMed ID: 27764786
[TBL] [Abstract][Full Text] [Related]
33. B7-H3 over expression in prostate cancer promotes tumor cell progression.
Yuan H; Wei X; Zhang G; Li C; Zhang X; Hou J
J Urol; 2011 Sep; 186(3):1093-9. PubMed ID: 21784485
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
[TBL] [Abstract][Full Text] [Related]
35. Clinical Significance of the Expression of Co-Stimulatory Molecule B7-H3 in Papillary Thyroid Carcinoma.
Zhao B; Huang Z; Zhu X; Cai H; Huang Y; Zhang X; Zhang Z; Lu H; An C; Niu L; Li Z
Front Cell Dev Biol; 2022; 10():819236. PubMed ID: 35493085
[No Abstract] [Full Text] [Related]
36. Expression status of PD-L1 and B7-H3 in mesothelioma.
Matsumura E; Kajino K; Abe M; Ohtsuji N; Saeki H; Hlaing MT; Hino O
Pathol Int; 2020 Dec; 70(12):999-1008. PubMed ID: 33027549
[TBL] [Abstract][Full Text] [Related]
37. B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration.
Kim GE; Kim NI; Park MH; Lee JS
Tumour Biol; 2018 Nov; 40(11):1010428318815032. PubMed ID: 30486739
[TBL] [Abstract][Full Text] [Related]
38. A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer.
Fauci JM; Straughn JM; Ferrone S; Buchsbaum DJ
Gynecol Oncol; 2012 Nov; 127(2):420-5. PubMed ID: 22910694
[TBL] [Abstract][Full Text] [Related]
39. B7-H3 expression in upper tract urothelial carcinoma associates with adverse clinicopathological features and poor survival.
Koyama Y; Morikawa T; Miyama Y; Miyakawa J; Kawai T; Kume H; Sawabe M; Ushiku T
Pathol Res Pract; 2020 Dec; 216(12):153219. PubMed ID: 33049447
[TBL] [Abstract][Full Text] [Related]
40. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.
Zhao SG; Lehrer J; Chang SL; Das R; Erho N; Liu Y; Sjöström M; Den RB; Freedland SJ; Klein EA; Karnes RJ; Schaeffer EM; Xu M; Speers C; Nguyen PL; Ross AE; Chan JM; Cooperberg MR; Carroll PR; Davicioni E; Fong L; Spratt DE; Feng FY
J Natl Cancer Inst; 2019 Mar; 111(3):301-310. PubMed ID: 30321406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
